High levels of TNF alpha in a tumor prove to be an independent prognostic indicator for a favorable course of colorectal cancer.
The journal Science named cancer immunotherapy as "the breakthrough of the year"; but challenges still remain to overcome tumor immune suppression and genomic instability.
A gene expression signature has been discovered that may lead to new immune therapies for patients with lung cancer.
A two-step personalized immunotherapy therapy treatment, which involved a dendritic cell vaccine using the patient's own tumor followed by adoptive T-cell therapy, triggered antitumor immune responses in four of six patients.
Creating T cells that recognize two different antigens on a tumor cell rather than just one could lead to more precisely targeted immunotherapy.
A newfound predictor of prostate stem cell antigen (PCSA) expression in bladder cancer could improve treatment efficacy in this disease.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient.
Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.
Plant-based drugs primarily used in the treatment of heart failure and arrhythmias have now been found to exert anticancer effects.
Daclizumab, which prevents organ rejection after renal transplant, improved survival in persons with breast cancer receiving a therapeutic vaccine.
A vaccine significantly increased survival in mice with breast cancer when given with the hormonal therapy letrozole, but not with tamoxifen.
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia rose from 83.7% for 1990-1994 to 90.4% for 2000-2005.
Combination therapy may be a promising treatment approach for patients with advanced melanoma who experience the abscopal effect.
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
Many women with early breast cancer experienced a sustained immune response after immunization with a vaccine that fights HER2, and this may reduce their risk for more invasive cancer.
A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
Learning you have breast cancer doesn't stop your life. This guide helps provide more information to African American women about what to do once a cancer diagnosis is made and what the next steps should be.
In November and December 2011, the FDA approved a number of new cancer drugs. Highlights include cetuximab for head and neck cancer, Hemacord, and asparaginase Erwinia chrysanthemi for ALL.
A common amino acid may help restore function to cancer-fighting T-cells in persons with glioblastoma, say researchers.
A quadrivalent human papillomavirus (HPV) vaccine to prevent anal cancer was shown to be safe and effective in a trial of healthy men who have sex with men.
Recent study results suggest that a targeted immunotherapy based on a poxvirus may make chemotherapy for advanced non-small cell lung cancer more effective and slow disease progression.
People with cancer who are being treated with antineoplastic agents should undergo routine testing for thyroid abnormalities.
In persons with stage III melanoma, frailty—not age—was associated with decreased disease-free survival and distant disease-free survival, and with more surgical complications.
A recently FDA-approved treatment and an experimental BRAF inhibitor offer hope to patients with metastatic melanoma.
Inducing vitiligo in persons with melanoma might enhance the natural immune response of these patients, according to data yielded by a recent study.
Omega-3 fatty acids could be a safe booster for tamoxifen, helping to produce a greater expression of genes that indicate lower cancer severity than seen with corn oil in an animal model.
A newly identified protein is reportedly the first CD19-specific recombinant human protein with potent anti-leukemic activity against B-lineage acute lymphoblastic leukemia (ALL).
Immune cells targeting just two cancer-related proteins in melanoma cells largely shrunk the tumors and kept the melanoma at bay for more than 36 weeks post-injection.
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Late-Stage Lung Cancer Often Overtreated
- Biomarker May Predict Prognosis for Targeted Therapy in Patients With HER2-Negative Breast Cancer
- New Approach Tackles Hormone Therapy Resistance in Breast Cancer
- Patients With Multiple Myeloma Vulnerable to Financial Toxicity Due to Costly Treatments
- Artificial Intelligence May Better Predict Response in Breast Cancer Treatment
- Blood Source May Explain Low Numbers of Circulating Tumor Cells in Liquid Biopsies
- Engineered Switch in Immune Cell Technology Makes Therapy More Precise, and Safer
- Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk
- Laparascopic Surgery Does Not Improve Outcomes Over Open Resection for Rectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|